WO2003040308A3 - Use of sterically stabilized cationic liposomes to efficiently deliver cpg oligonucleotides in vivo - Google Patents

Use of sterically stabilized cationic liposomes to efficiently deliver cpg oligonucleotides in vivo Download PDF

Info

Publication number
WO2003040308A3
WO2003040308A3 PCT/US2002/024235 US0224235W WO03040308A3 WO 2003040308 A3 WO2003040308 A3 WO 2003040308A3 US 0224235 W US0224235 W US 0224235W WO 03040308 A3 WO03040308 A3 WO 03040308A3
Authority
WO
Grant status
Application
Patent type
Prior art keywords
odn
sscl
encapsulating
cationic liposomes
type
Prior art date
Application number
PCT/US2002/024235
Other languages
French (fr)
Other versions
WO2003040308A2 (en )
Inventor
Dennis M Klinman
Ihsan Gursel
Ken J Ishii
Koji Kawakami
Bharat H Joshi
Raj K Puri
Original Assignee
Us Gov Health & Human Serv
Dennis M Klinman
Ihsan Gursel
Ken J Ishii
Koji Kawakami
Bharat H Joshi
Raj K Puri
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55561CpG containing adjuvants; Oligonucleotide containing adjuvants
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/38Medical treatment of vector-borne diseases characterised by the agent
    • Y02A50/408Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa
    • Y02A50/409Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa of the genus Leishmania i.e. Leishmaniasis, Sand-fly fever, phlebotomus fever, kala-azar, black fever or Dumdum fever
    • Y02A50/41Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa of the genus Leishmania i.e. Leishmaniasis, Sand-fly fever, phlebotomus fever, kala-azar, black fever or Dumdum fever the medicinal preparation containing antigens or antibodies, e.g. vaccines, antisera
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/38Medical treatment of vector-borne diseases characterised by the agent
    • Y02A50/408Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa
    • Y02A50/411Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa of the genus Plasmodium, i.e. Malaria
    • Y02A50/412Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa of the genus Plasmodium, i.e. Malaria the medicinal preparation containing antigens or antibodies, e.g. vaccines, antisera
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/38Medical treatment of vector-borne diseases characterised by the agent
    • Y02A50/417Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a helminth, i.e. Helmanthiasis
    • Y02A50/423Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a helminth, i.e. Helmanthiasis the helminth being a trematode flatworm of the genus Schistosoma, i.e. Schistosomiasis or bilharziasis

Abstract

Sterically stabilized cationic liposomes (SSCL) encapsulating a K type oligodeoxynucleotide (ODN) including a CpG motif are disclosed. These SSCL encapsulating a K type ODN can be used to effectively deliver the ODN to a cell. A novel method is also disclosed for producing the SSCL encapsulating the K type ODN. Administration of the SSCL encapsulating a K type ODN and a chemotherapeutic agent, such as a chimeric molecule comprising a targeting molecule selected from the group consisting of an IL-13, and an anti-IL-13 receptor antibody; and an effector molecule selected from the group consisting of a Pseudomonas exotoxin, a Diphtheria toxin, and a radionuclide, can be used to dramatically reduce the growth of solid tumors.
PCT/US2002/024235 2001-07-27 2002-07-29 Use of sterically stabilized cationic liposomes to efficiently deliver cpg oligonucleotides in vivo WO2003040308A3 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US30828301 true 2001-07-27 2001-07-27
US60/308,283 2001-07-27
US20640702 true 2002-07-25 2002-07-25
US10/206,407 2002-07-25

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10484991 US7666674B2 (en) 2001-07-27 2002-07-29 Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
US12647320 US20100104507A1 (en) 2001-07-27 2009-12-24 Use of sterically stabilized cationic liposomes to efficiently deliver cpg oligonucleotides in vivo

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US20640702 Continuation-In-Part 2002-07-25 2002-07-25

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12647320 Continuation US20100104507A1 (en) 2001-07-27 2009-12-24 Use of sterically stabilized cationic liposomes to efficiently deliver cpg oligonucleotides in vivo

Publications (2)

Publication Number Publication Date
WO2003040308A2 true WO2003040308A2 (en) 2003-05-15
WO2003040308A3 true true WO2003040308A3 (en) 2003-11-20

Family

ID=26901314

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/024235 WO2003040308A3 (en) 2001-07-27 2002-07-29 Use of sterically stabilized cationic liposomes to efficiently deliver cpg oligonucleotides in vivo

Country Status (1)

Country Link
WO (1) WO2003040308A3 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9404126B2 (en) 2006-06-12 2016-08-02 Kuros Biosciences Ag Processes for packaging aggregated oligonucleotides into virus-like particles of RNA bacteriophages

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP2196217A1 (en) 2001-09-14 2010-06-16 Cytos Biotechnology AG Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
EP1572122A4 (en) * 2002-11-01 2008-04-09 Us Gov Health & Human Serv Method of preventing infections from bioterrorism agents with immunostimulatory cpg oligonucleotides
CA2502015A1 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5' cpg nucleic acids and methods of use
US7537767B2 (en) 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
CA2544240A1 (en) * 2003-07-22 2005-02-17 Cytos Biotechnology Ag Cpg-packaged liposomes
EP1663316A2 (en) * 2003-09-25 2006-06-07 Coley Pharmaceutical Group, Inc. Nucleic acid lipophilic conjugates
RU2451523C2 (en) 2005-12-14 2012-05-27 Цитос Биотехнологи Аг Particles packed in immunostimulating nucleic acid that intended for hypersensitivity treatment
US9394369B2 (en) * 2011-01-03 2016-07-19 The Regents Of The University Of California Luminescent porous silicon nanoparticles for targeted delivery and immunization
KR101465365B1 (en) * 2013-10-15 2014-11-25 성균관대학교산학협력단 Lipid-supported polymeric functional particles and method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6008202A (en) * 1995-01-23 1999-12-28 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US6218371B1 (en) * 1998-04-03 2001-04-17 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6008202A (en) * 1995-01-23 1999-12-28 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US6218371B1 (en) * 1998-04-03 2001-04-17 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BEI ET AL.: "The use of a cationic liposome formulation (DOTAP) mixed with a recombinant tumor-associated antigen to induce immune responses and protective immunity in mice", JOURNAL OF IMMUNOTHERAPY, vol. 21, no. 3, 1998, pages 159 - 169, XP002963675 *
FRIEDMARK ET AL.: "Cationic lipids enhance cytokine and cell influx levels in the lung following administration of plasmid: cationic lipid complexes", THE JOURNAL OF IMMUNOLOGY, vol. 160, 1998, pages 4580 - 4586, XP002067073 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9404126B2 (en) 2006-06-12 2016-08-02 Kuros Biosciences Ag Processes for packaging aggregated oligonucleotides into virus-like particles of RNA bacteriophages

Also Published As

Publication number Publication date Type
WO2003040308A2 (en) 2003-05-15 application

Similar Documents

Publication Publication Date Title
WO2002009754A1 (en) Novel remedies for cancer
CA2309727A1 (en) Methods for encapsulating nucleic acids in lipid bilayers
Di Paolo et al. Drug delivery systems: application of liposomal anti-tumor agents to neuroectodermal cancer treatment
WO2003045965A3 (en) Compositions of nucleic acids and cationic aminoglycosides and methods of using and preparing the same
WO2001000244A3 (en) METHODS OF TREATMENT USING ANTI-ErbB ANTIBODY-MAYTANSINOID CONJUGATES
WO2002070438A3 (en) Compositions for delivering bisphosphonates
CA2387058A1 (en) Injection vehicle for polymer-based formulations
WO2002009767A3 (en) Therapeutic polyanhydride compounds for drug delivery
WO2002009768A3 (en) Therapeutic polyesters and polyamides
WO2002096367A3 (en) Targeted multivalent macromolecules
WO2003082853A8 (en) New compounds
KR100938541B1 (en) Biosynthetic method for preparation of antitumor agent epirubicin, novel glycosylated anthracycline derivatives and their preparation methods
JP5755827B2 (en) Oligonucleotide analogs phosphate with enhanced immunostimulatory activity has been modified
KR100989238B1 (en) Biosynthetic method for preparation of antitumor agent epirubicin, novel glycosylated anthracycline derivatives and their preparation methods
CA2546730A1 (en) A method for the treatment of malignant diseases by inhibiting nucleolin
WO2000040203A3 (en) Polymeric delivery agents and delivery agent compounds
JP2005027569A (en) New dna conjugate and antisense agent with the same as active ingredient
WO2002080965A3 (en) Vaccine composition
CA2263705A1 (en) Novel sandwich liposome complexes comprising a biologically active agent
Corthier et al. Molecular weight of cytotoxin (s) produced in vivo by Clostridium difficile.
WO2001055370A3 (en) MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES
Wilson et al. Lipid-based delivery of CpG oligodeoxynucleotides for cancer immunotherapy
WO2003028657A3 (en) Compositions for oral gene therapy and methods of using same
WO2002062378A3 (en) Hyperblebbing bacterial strains and use thereof for production of vaccines
WO2003020949A3 (en) Targeted nucleic acid constructs and uses related thereto

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10484991

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP